Señales en vivo de OMER | Maximiza tus Ganancias con Getagraph.com

VENDER 117769 min ago

@ $3.64

Emitido: 13 feb 2024 @ 15:55

Retorno: 2.61%

Señal anterior: feb 9 - 13:51

Señal anterior: Comprar

Retorno: -3.84 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	158 316
Volumen promedio	459 452
Capitalización de mercado	216.13M
EPS	$0 ( 2024-04-01 )
Próxima fecha de ganancias	( $-0.580 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.340
ATR14	$0.00600 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Demopulos Gregory A Md	Buy	725 000	Stock Option (right to buy)
2024-04-25	Jacobsen Michael A	Buy	100 000	Stock Option (right to buy)
2024-04-25	Cancelmo Peter B	Buy	100 000	Stock Option (right to buy)
2023-11-17	Demopulos Gregory A Md	Buy	15 000	Common Stock
2023-11-15	Demopulos Peter A Md	Buy	10 000	Common Stock

INSIDER POWER
98.87
Last 99 transactions
Buy: 4 085 039 \| Sell: 554 578

Volumen Correlación

Largo: 0.42 (neutral)

Corto: 0.58 (weak)

Signal:(67.675) Neutral

Omeros Corp Correlación

10 Correlaciones Más Positivas
ADRE	0.828
LNSR	0.824
IGMS	0.801

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Omeros Corp Correlación - Moneda/Commodity

-0.56
( weak negative )

0.00
( neutral )

-0.68
( moderate negative )

0.61
( weak )

Omeros Corp Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-920 000 (0.00 %)
EPS:	$-1.880

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-920 000 (0.00 %)
EPS:	$-1.880

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-952 000 (0.00 %)
EPS:	$0.460

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$3.12

Financial Reports:

No articles found.

Omeros Corp

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.